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Figure 2. Expression pattern of major signals by SPB-X down- or up-
regulation in hBMSCs. (A and B) Genes and proteins expression in lenti-
im6 transduced hBMSCs. (C) Construct of SPB-X overexpression vector. (D)
Fluorescent microscopy of hSPB-X overexpressed BMSCs. (E and F) Rq-PCR
and Western blotting results of hSPB-X overexpressed BMSCs.
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conﬁrmed that the down-regulation of hedgehog signals by miR-im6
can suppress expression of wnt signal molecules (Wnt3a, Wnt7a,
Wnt6, Wnt9b and b-catenin)(Fig 2b). On the contrary, indian hedgehog
was transiently up-regulated by overexpression of SPB-X in hBMSCs
(Fig 2c-f).
Transcription factor SPB-X and Wnt6 are target genes of hsa-miR-
im6: As shown in Fig 3c, luciferase activitieswere signiﬁcantly decreased
in Hela cells was co-transfected with luciferase reporter vectors harbor-
ing SPB-X or WNT6 3’UTR and hsa-miR-im6 mimic. This result demon-
strates that SPB-X and WNT6 are target genes of hsa-miR-im6.
SPB-X knockout induce down-regulation of indian hedgehog: We
investigated SPB K/O effects using mouse MSCs isolated from SPB K/OFigure 4. Effect of SPB-X knockout in chondrogenic differentiation of
mouse MSCs. (A) Ratio of GAG/DNAmeasured in mouse MSC pellets after 3
weeks of culture. (B)Gross appearance ofmouseMSCs chondrogenic pellets.
(C) Protein expression of major hedgehog signal molecules, chondrogenic
differentiation and hypertrophic markers in mouse MSCs chondrogenic
pellets. (D) Blocking mechanism of chondrocyte hypertrophy by miR-im6.mouse. GAG/DNA ratio and safranin-O staining results show that
chondrogenic potentials of SPB K/O MSC is similar to that of wild
type MSC (Fig 4a and b). However, we conﬁrmed that expressions of
IHH, PTCH1, WNT6 and WNT9b were suppressed in chondrogenic
pellet of SPB K/O MSC when compared with that of wild type MSC
(Fig 4c).
Conclusions: Our results show that miR-im6 acts as a positive regulator
of chondrogenic differentiation as well as a hypertrophy blocker in
BMSCs by direct decreasing the transcription factor SBP-X and WNT
expression in PTHrP-IHH negative feedback inhibition pathway (Fig 4d).
Also, SBP-X is major transcription factor regulating indian hedgehog
protein inMSC chondrogenesis. To our knowledge, this is the ﬁrst report
showing that a speciﬁc microRNA, miR-im6, plays a crucial role in the
course of chondrogenesis.
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Purpose: Lower back pain (LBP) is the #1 global cause for years lived
with disability, where 80% of the population will develop LBP at some
stage of their lifetime, leading to substantial socioeconomic impact.
Intervertebral disc degeneration (IVDD) is implicated in 40% of LBP.
Current options for IVDD treatment includes surgical intervention
(spinal fusion, disc replacement) or palliative care, but there are no
available disease modifying treatments. Recent studies demonstrated
great promise with mesenchymal stem cell (MSC) therapy in IVDD,
however pre-clinical studies were restricted to small animal (rodent)
models which are not representative of human disease. We have pre-
viously developed a large animal model of ovine IVDD which repro-
duces many of the pathological features of human disease, and used this
to assess the efﬁcacy of bone marrow derived mesenchymal stem cells
(BMMSCs) for the treatment of IVDD.
Methods: A single pool of heterologous ovine BMMSCswas isolated and
culture expanded up to passage 8 for subsequent injections (Fig 1A).
These BMMSCs were capable of adipogenic, osteogenic and chondro-
genic differentiation. IVD lesion was induced by a 6 x 20mm annularFigure 1. Experimental design.Ă
Figure 2. A. Representative X-ray images at IVD level L3L4 from acute long
term group. B. Disc height measurements pre- and post-injection. * P <
0.05 to BS-injected discs.
Figure 3. Selected lesion IVD catabolic enzyme gene expressions. Data
presented as fold change to NOC. *P < 0.05 between PBS and MSC.
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BMMSCs (107 cells/0.2ml PBS/disc) or PBS only (0.2ml) were injected
into the NP after 4 or 12 weeks of induction of IVDD (n¼6 sheep/group),
aftera further 8, 22 or 14week recoveryperiod the sheepwere sacriﬁced,
generating 3 study groups: Acute short term (Short), Acute long term
(Long), and Established IVDD (Est) (Fig 1B). The outcome measures for
this studywere histology, imaging (MRI, X-ray), gene proﬁling (qRTPCR),
biomechanical testing and biochemical composition analyses (Fig 1A).
Results: Induced IVD lesion led to siginﬁcant loss of disc height in all
lumbar levels (PBS injected, Fig 2). A re-attainment to 90-95% of pre-
lesion disc height was evident in MSC-injected discs (Fig 2). In the
Established group, MSC injected discs showed a recovery of proteo-
glycan (GAG) content to levels in NOC IVDs. Increased metal-
loproteinase activity is a feature of the ovine IVDD lesion model. It was
therefore signiﬁcant that MSC injection either normalised or inhibited
MMP2, 9, 13, ADAMTS4 or 5 expression in most lesion IVD tissue zones
(Fig 3). Biomechanical properties of IVDD at 3 and 6 months showed no
change in total range of motion, but signiﬁcantly increased neutral zone
measurements (NZ: range of displacement when IVD was unloaded
during movement), whereas BMMSC injected discs in Short and Est
groups returned NZ to NOC levels. Histology showed signiﬁcant
reduction in the propagation of the annular lesions in the MSC injected
discs, whereas in PBS injected discs the initial outer annular lesions
propagated through the mid-inner AF into and around the NP, and even
affecting the contralateral AF.
Conclusions: BMMSCs demonstrated considerable therapeutic promise
not only for the repair of a degenerate disc but also prevents/reduces
the progressive changes in established annular lesion: 1. Repair of
annular lesions and reduced IVDD pathology, 2. Recovery in disc
heights, GAG content of NP in Established disease, and biomechanical
properties of lesion discs, 3. Down-regulated MMP2, 9, 13, ADAMTS4
and 5 gene expressions. We identiﬁed a potential mechanism of action
of BMMSC to be the modulation of metalloproteinase expression. This
study has shown for the ﬁrst time in a large animal model relevant to
the human condition that BMMSC represent a clinically relevant ther-
apy for IVDD.42
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Purpose: The control of proliferation versus differentiation of mesen-
chymal stem cells (MSCs) is crucial for tissue homeostasis, remodelling,
and repair, as well as for tissue engineering strategies employing MSCs.
The transcriptional co-activator Yes-Associated Protein (YAP) has been
emerging as a key regulator of stem cells in tissues and organs such as
liver, intestine, brain and muscle. The purpose of this study was to
investigate whether YAP plays a role in regulating proliferation and
chondrogenic differentiation of MSCs.
Methods: Total YAP and phosphorylated (p)YAP were detected in con-
junction with nucleoside labels (to identify putative MSCs) by immu-
nostaining on parafﬁn sections of C57Bl/6mouse knee joints from either
